Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

14,000 people help test new blood test for early cancer detection

NCT ID NCT05205967

Knowledge-focused Sponsor: GRAIL, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking about 14,000 adults who chose to take the Galleri® blood test, which looks for many types of cancer early. Researchers want to see how well the test works in real doctor's offices and how patients feel about it. The goal is to learn more about using this test in routine care, not to treat cancer directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14,633 people

The number who actually took part.

Started

Aug 2021

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll approximately 14,000 participants who meet the defined eligibility criteria.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Participant has the ability to understand and the willingness to sign a written informed consent form (ICF); * Participant is at least 22 years old at the time of consent; * A provider or their designee has ordered the Galleri® test; and * Participant has the ability to comprehend the participant questionnaires. Exclusion Criteria: * There are no exclusions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Early detection of cancer

Contacts and locations

Locations

  • Boston VA Research Institute (VA Boston)

    Boston, Massachusetts, 02111-1750, United States

  • Carolina Blood and Cancer Care Associate

    Lancaster, South Carolina, 29720, United States

  • Carolina Blood and Cancer Care Associates

    Rock Hill, South Carolina, 29732, United States

  • James A. Haley Veterans Hospital (VA Tampa)

    Tampa, Florida, 33612, United States

  • Providence

    Burbank, California, 91505, United States

  • Providence

    Portland, Oregon, 97213, United States

  • Providence, Mission

    Mission Viejo, California, 92691, United States

  • Providence, Orange County

    Orange, California, 92868, United States

  • Providence, St. Jude

    Fullerton, California, 92835, United States

  • Southeast Louisiana Veterans Health Care System (SLVHCS) (VA New Orleans)

    New Orleans, Louisiana, 70119, United States

  • VA Miami Health Care System

    Miami, Florida, 33125, United States

  • VA Pittsburgh Healthcare System

    Pittsburgh, Pennsylvania, 15240, United States

  • VA Salt Lake City Health Care System (VASLCHCS)

    Salt Lake City, Utah, 84148, United States

  • VA Wilkes Barre Medical Center

    Wilkes-Barre, Pennsylvania, 18711, United States

  • Vincere Cancer Center

    Scottsdale, Arizona, 85260, United States

  • WVU University Town Centre Family Medicine

    Morgantown, West Virginia, 26501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.